Development of Novel Neratinib and Docetaxel Core-Loaded and Trastuzumab Surface-Conjugated Nanoparticle for Treatment of HER-2 Positive Breast Cancer.

Pharmaceutics · 2025 · PMC12567355 · PMID 41155902

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

highly significantp = 0.01actually significant

The results ( Figure 11 b) revealed a highly significant difference between TRZ−NP and NTB+DTX−NP ( p = 0.01), NTB+DTX−NP and PBS ( p = 0.01), and a strongly significant difference between TRZ−NP and PBS ( p = 0.001).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.